CERo Therapeutics raises ~$750k in Series D financing; first-in-human dosing under way

CERO THERAPEUTICS HOLDINGS, INC.

Gross proceeds from additional closing ~$750k; total Series D up to $8M with $5M previously issued.
Series D convertible preferred converts to common; additional $2.25M possible at investors' option.
Proceeds to support clinical development of CAR-T candidate CER-1236, including IND allowances and site activation at MDACC.
Company reports first-in-human dosing in AML for CER-1236, a TIM-4L-targeted autologous CAR-T.
CEO Chris Ehrlich cites continued investor support and clinical progress.

item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.